When a drug is going to be developed, not only does an active substance have to be developed - it must also be an effective drug preparation, so that the substance can be properly absorbed by the body. RISE is collaborating with the pharmaceutical company Umecrine Cognition, which is developing an effective new drug, which can help patients who have hitherto received inadequate treatment.
The pharmaceutical company Umecrine Cognition develops drugs for neurological disorders of the central nervous system, such as the disease hepatic encephalopathy. It is a serious neurological and psychiatric condition associated with liver disease, which in the worst case can lead to death. There is currently no approved treatment for these neurological disorders.
How can we help you?
RISE offers expertise and support along the entire drug development process. Fill out the form and we will be in touch!
Problem solving through lipids
But there are more challenges than that – the substances you work with in pharmaceutical products are, in many cases, sparingly soluble. This problem has been solved by developing a dosage form with significantly better solubility, thanks to the addition of lipids which have been shown to produce better results than other types of formulations previously tested.
"The lipids give us amazing opportunities to dissolve sparingly soluble substances. At the same time they are taken care of by our physiological digestive system for the absorption of fats", says Nicolaas Schipper.
